Colorectal cancer

The Lancet

Volumn 375, Issue 9719, 2010, Pages 1030-1047

  Cunningham, David ^a   Atkin, Wendy ^b   Lenz, Heinz Josef ^c   Lynch, Henry T ^d   Minsky, Bruce ^e   Nordlinger, Bernard ^f   Starling, Naureen ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^f HÔPITAL AMBROISE PARÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; PROTEIN MLH1;

ABSCESS; BLOOD TOXICITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CHROMOSOMAL INSTABILITY; CLINICAL FEATURE; CLINICAL TRIAL; COLON CARCINOGENESIS; COLON RESECTION; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DEHYDRATION; DIARRHEA; GENE MUTATION; HUMAN; HYPERTENSION; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MULTIMODALITY CANCER THERAPY; NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCULT BLOOD; ONCOGENE K RAS; OVERALL SURVIVAL; PAIN; POSTOPERATIVE CARE; PREOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; RASH; REVIEW; RISK ASSESSMENT; RISK FACTOR; SKIN TOXICITY; TRANSRECTAL ULTRASONOGRAPHY;

EID: 77949437015     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60353-4     Document Type: Review

References (216)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Vogelstein B., Fearon E.R., Hamilton S.R., et al. Genetic alterations during colorectal-tumor development. N Engl J Med 319 (1988) 525-532
3. Noffsinger A.E. Serrated polyps and colorectal cancer: new pathway to malignancy. Annu Rev Pathol 4 (2009) 343-364
4. Lengauer C., Kinzler K.W., and Vogelstein B. Genetic instabilities in human cancers. Nature 396 (1998) 643-649
5. Lothe R.A., Peltomaki P., Meling G.I., et al. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 53 (1993) 5849-5852
6. Vogelstein B., Fearon E.R., Hamilton S.R., et al. Genetic alterations during colorectal-tumor development. N Engl J Med 319 (1988) 525-532
7. Vogelstein B., Fearon E.R., Kern S.E., et al. Allelotype of colorectal carcinomas. Science 244 (1989) 207-211
8. Aaltonen L.A., Peltomaki P., Leach F.S., et al. Clues to the pathogenesis of familial colorectal cancer. Science 260 (1993) 812-816
9. Ionov Y., Peinado M.A., Malkhosyan S., Shibata D., and Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363 (1993) 558-561
10. Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol 21 (2003) 1174-1179
11. Kane M.F., Loda M., Gaida G.M., et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 57 (1997) 808-811
12. Cunningham J.M., Christensen E.R., Tester D.J., et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 58 (1998) 3455-3460
13. Toyota M., Ahuja N., Ohe-Toyota M., Herman J.G., Baylin S.B., and Issa J.P. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 96 (1999) 8681-8686
14. Shen L., Toyota M., Kondo Y., et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA 104 (2007) 18654-18659
15. Young J., Jenkins M., Parry S., et al. Serrated pathway colorectal cancer in the population: genetic consideration. Gut 56 (2007) 1453-1459
16. Colorectal cancer risk factors (2009). http://www.cdc.gov/cancer/colorectal/basic_info/risk_factors.htm (accessed Feb 2, 2010).
17. von Roon A.C., Reese G., Teare J., Constantinides V., Darzi A.W., and Tekkis P.P. The risk of cancer in patients with Crohn's disease. Dis Colon Rectum 50 (2007) 839-855
18. Eaden J.A., Abrams K.R., and Mayberry J.F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48 (2001) 526-535
19. Itzkowitz S.H., and Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology 126 (2004) 1634-1648
20. Triantafillidis J.K., Nasioulas G., and Kosmidis P.A. Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res 29 (2009) 2727-2737
21. Hampel H., Frankel W.L., Martin E., et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 26 (2008) 5783-5788
22. Watson P., Vasen H., Mecklin J.-P., et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 123 (2008) 444-449
23. Barrow E., Robinson L., Alduaij W., et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet 75 (2009) 141-149
24. Bussey H. Familial polyposis coli: Family studies, histopathology, differential diagnosis, and results of treatment (1975), Johns Hopkins University Press, Baltimore
25. Bulow S., Faurschou N.T., Bulow C., Bisgaard M.L., Karlsen L., and Moesgaard F. The incidence rate of familial adenomatous polyposis. Results from the Danish Polyposis Register. Int J Colorectal Dis 11 (1996) 88-91
26. Vasen H.F., Watson P., Mecklin J.P., and Lynch H.T. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116 (1999) 1453-1456
27. Lindor N.M., Rabe K., Petersen G.M., et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 293 (2005) 1979-1985
28. Llor X., Pons E., Xicola R.M., et al. Differential features of colorectal cancers fulfilling Amsterdam criteria without involvement of the mutator pathway. Clin Cancer Res 11 (2005) 7304-7310
29. Umar A., Boland C.R., Terdiman J.P., et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96 (2004) 261-268
30. Lynch H.T., Boland C.R., Rodriguez-Bigas M.A., Amos C., Lynch J.F., and Lynch P.M. Who should be sent for genetic testing in hereditary colorectal cancer syndromes?. J Clin Oncol 25 (2007) 3534-3542
31. Engel C., Forberg J., Holinski-Feder E., et al. Novel strategy for optimal sequential application of clinical criteria, immunohistochemistry and microsatellite analysis in the diagnosis of hereditary nonpolyposis colorectal cancer. Int J Cancer 118 (2006) 115-122
32. Lynch H.T., Lynch J.F., and Lynch P.M. Toward a consensus in molecular diagnosis of hereditary nonpolyposis colorectal cancer (Lynch syndrome). J Natl Cancer Inst 99 (2007) 261-263
33. Bessa X., Balleste B., Andreu M., et al. A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening. Clin Gastroenterol Hepatol 6 (2008) 206-214
34. Senter L., Clendenning M., Sotamaa K., et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 135 (2008) 419-428
35. Gerard J., Azria D., Gourgou-Bourgade S., et al. Randomized multicenter phase III trial comparing two neoadjuvant chemoradiotherapy (CT-RT) regimens (RT45-Cap versus RT50-Capox) in patients (pts) with locally advanced rectal cancer (LARC): Results of the ACCORD 12/0405 PRODIGE 2. Proc ASCO Meeting Abstracts 27 18 suppl (2009) LBA4007
36. Aschele C., Pinto C., Cordio S., et al. Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: Pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase III trial. Proc ASCO Meeting Abstracts 27 18 suppl (2009) CRA4008
37. Crane C.H., Eng C., Feig B.W., et al. Phase II trial of neoadjuvant bevacizumab (BEV), capecitabine (CAP), and radiotherapy (XRT) for locally advanced rectal cancer. Proc ASCO Meeting Abstracts 26 15 suppl (2008) 4091
38. Willett C.G., Duda D.G., di T.E., et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 27 (2009) 3020-3026
39. Rodel C., Arnold D., Hipp M., et al. Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys 70 (2008) 1081-1086
40. Mohiuddin M., Winter K., Mitchell E., et al. Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol 24 (2006) 650-655
41. Wong S.J., Winter K., Meropol N.J., et al. RTOG 0247: A randomized phase II study of neoadjuvant capecitabine and irinotecan versus capecitabine and oxaliplatin with concurrent radiation therapy for locally advanced rectal cancer. Proc ASCO Meeting Abstracts 26 15 suppl (2008) 4021
42. Fernández-Martos C., Aparicio J., Salud A., et al. Multicenter randomized phase II study of chemoradiation (CRT) followed by surgery (S) and chemotherapy (CT) versus induction CT followed by CRT and S in high-risk rectal cancer: GCR-3 final efficacy and safety results. Proc ASCO Meeting Abstracts 27 (2009) 4103
43. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 11 (2009) 35-41
44. Jarvinen H.J., Aarnio M., Mustonen H., et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118 (2000) 829-834
45. Dove-Edwin I., Sasieni P., Adams J., and Thomas H.J. Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. BMJ 331 (2005) 1047
46. Lynch H.T., and de la C.A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet 36 (1999) 801-818
47. Schmeler K.M., Lynch H.T., Chen L.M., et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354 (2006) 261-269
48. American Cancer Society. Detailed guide: colon and rectum cancer. What are the risk factors for colorectal cancer? (May 18, 2009). http://www.cancer.org/docroot/CRI/content/CRI_2_4_2X_What_are_the_risk_factors_for_colon_and_rectum_cancer.asp (accessed Feb 2, 2010).
49. Verdecchia A., Francisci S., Brenner H., et al. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 8 (2007) 784-796
50. Tappenden P., Chilcott J., Eggington S., Sakai H., Karnon J., and Patnick J. Option appraisal of population-based colorectal cancer screening programmes in England. Gut 56 (2007) 677-684
51. Loeve F., Brown M.L., Boer R., van B.M., van Oortmarssen G.J., and Habbema J.D. Endoscopic colorectal cancer screening: a cost-saving analysis. J Natl Cancer Inst 92 (2000) 557-563
52. Towler B., Irwig L., Glasziou P., Kewenter J., Weller D., and Silagy C. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult. BMJ 317 (1998) 559-565
53. Collins J.F., Lieberman D.A., Durbin T.E., and Weiss D.G. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med 142 (2005) 81-85
54. Steele R.J., Parker R., Patnick J., et al. A demonstration pilot trial for colorectal cancer screening in the United Kingdom: a new concept in the introduction of healthcare strategies. J Med Screen 8 (2001) 197-202
55. Benson V.S., Patnick J., Davies A.K., Nadel M.R., Smith R.A., and Atkin W.S. Colorectal cancer screening: a comparison of 35 initiatives in 17 countries. Int J Cancer 122 (2008) 1357-1367
56. Pignone M., Saha S., Hoerger T., and Mandelblatt J. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the US Preventive Services Task Force. Ann Intern Med 137 (2002) 96-104
57. Whitlock E.P., Lin J.S., Liles E., Beil T.L., and Fu R. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 149 (2008) 638-658
58. Castiglione G., Grazzini G., Miccinesi G., et al. Basic variables at different positivity thresholds of a quantitative immunochemical test for faecal occult blood. J Med Screen 9 (2002) 99-103
59. Atkin W.S., Hart A., Edwards R., et al. Single blind, randomised trial of efficacy and acceptability of oral picolax versus self administered phosphate enema in bowel preparation for flexible sigmoidoscopy screening. BMJ 320 (2000) 1504-1508
60. Selby J.V., Friedman G.D., Quesenberry Jr. C.P., and Weiss N.S. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 326 (1992) 653-657
61. Newcomb P.A., Storer B.E., Morimoto L.M., Templeton A., and Potter J.D. Long-term efficacy of sigmoidoscopy in the reduction of colorectal cancer incidence. J Natl Cancer Inst 95 (2003) 622-625
62. Atkin W.S., Edwards R., Wardle J., et al. Design of a multicentre randomised trial to evaluate flexible sigmoidoscopy in colorectal cancer screening. J Med Screen 8 (2001) 137-144
63. Segnan N., Senore C., Andreoni B., et al. Baseline findings of the Italian multicenter randomized controlled trial of "once-only sigmoidoscopy"-SCORE. J Natl Cancer Inst 94 (2002) 1763-1772
64. Weissfeld J.L., Schoen R.E., Pinsky P.F., et al. Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial. J Natl Cancer Inst 97 (2005) 989-997
65. Bretthauer M., Gondal G., Larsen K., et al. Design, organization and management of a controlled population screening study for detection of colorectal neoplasia: attendance rates in the NORCCAP study (Norwegian Colorectal Cancer Prevention). Scand J Gastroenterol 37 (2002) 568-573
66. Pignone M., Rich M., Teutsch S.M., Berg A.O., and Lohr K.N. Screening for colorectal cancer in adults at average risk: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 137 (2002) 132-141
67. Atkin W.S., Northover J., Cuzick J., and Whynes D.K. Prevention of colorectal cancer by once-only sigmoidoscopy. Lancet 341 (1993) 736-740
68. Lakoff J., Paszat L.F., Saskin R., and Rabeneck L. Risk of developing proximal versus distal colorectal cancer after a negative colonoscopy: a population-based study. Clin Gastroenterol Hepatol 6 (2008) 1117-1121
69. Baxter N.N., Goldwasser M.A., Paszat L.F., Saskin R., Urbach D.R., and Rabeneck L. Association of colonoscopy and death from colorectal cancer. Ann Intern Med 150 (2009) 1-8
70. Pignone M., Rich M., Teutsch S., Berg A., and Lohr K. Screening for colorectal cancer in adults. Systematic evidence review number 7 (2002), Agency for Healthcare Research and Quality, Rockville. http://www.ahrq.gov/clinic/serfiles.htm (accessed Feb 2, 2010).
71. Pox C., Schmiegel W., and Classen M. Current status of screening colonoscopy in Europe and in the United States. Endoscopy 39 (2007) 168-173
72. Regula J., Rupinski M., Kraszewska E., et al. Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N Engl J Med 355 (2006) 1863-1872
73. Halligan S., Altman D.G., Taylor S.A., et al. CT colonography in the detection of colorectal polyps and cancer: systematic review, meta-analysis, and proposed minimum data set for study level reporting. Radiology 237 (2005) 893-904
74. Pickhardt P.J., Hanson M.E., Vanness D.J., et al. Unsuspected extracolonic findings at screening CT colonography: clinical and economic impact. Radiology 249 (2008) 151-159
75. Vijan S., Hwang I., Inadomi J., et al. The cost-effectiveness of CT colonography in screening for colorectal neoplasia. Am J Gastroenterol 102 (2007) 380-390
76. Imperiale T.F., Ransohoff D.F., Itzkowitz S.H., Turnbull B.A., and Ross M.E. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 351 (2004) 2704-2714
77. Diehl F., Schmidt K., Durkee K.H., et al. Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology 135 (2008) 489-498
78. Fockens P. Advances in colonic imaging. Eur J Gastroenterol Hepatol 17 (2005) 783-784
79. Mauchley D.C., Lynge D.C., Langdale L.A., Stelzner M.G., Mock C.N., and Billingsley K.G. Clinical utility and cost-effectiveness of routine preoperative computed tomography scanning in patients with colon cancer. Am J Surg 189 (2005) 512-517
80. Mainenti P.P., Romano M., Imbriaco M., et al. Added value of CT colonography after a positive conventional colonoscopy: impact on treatment strategy. Abdom Imaging 30 (2005) 42-47
81. Copel L., Sosna J., Kruskal J.B., Raptopoulos V., Farrell R.J., and Morrin M.M. CT colonography in 546 patients with incomplete colonoscopy. Radiology 244 (2007) 471-478
82. Morrin M.M., Kruskal J.B., Farrell R.J., Goldberg S.N., McGee J.B., and Raptopoulos V. Endoluminal CT colonography after an incomplete endoscopic colonoscopy. AJR Am J Roentgenol 172 (1999) 913-918
83. Furukawa H., Ikuma H., Seki A., et al. Positron emission tomography scanning is not superior to whole body multidetector helical computed tomography in the preoperative staging of colorectal cancer. Gut 55 (2006) 1007-1011
84. Brown G., Radcliffe A.G., Newcombe R.G., Dallimore N.S., Bourne M.W., and Williams G.T. Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging. Br J Surg 90 (2003) 355-364
85. Bipat S., Glas A.S., Slors F.J., Zwinderman A.H., Bossuyt P.M., and Stoker J. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging. A meta-analysis. Radiology 232 (2004) 773-783
86. Fioole B., de Haas R.J., Wicherts D.A., et al. Additional value of contrast enhanced intraoperative ultrasound for colorectal liver metastases. Eur J Radiol 67 (2008) 169-176
87. Ward J. New MR techniques for the detection of liver metastases. Cancer Imaging 6 (2006) 33-42
88. Bipat S., van Leeuwen M.S., Comans E.F., et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis-meta-analysis. Radiology 237 (2005) 123-131
89. Truant S., Huglo D., Hebbar M., Ernst O., Steinling M., and Pruvot F.R. Prospective evaluation of the impact of [18F]fluoro-2-deoxy-D-glucose positron emission tomography of resectable colorectal liver metastases. Br J Surg 92 (2005) 362-369
90. Gonzalez-Moreno S., Gonzalez-Bayon L., Ortega-Perez G., and Gonzalez-Hernando C. Imaging of peritoneal carcinomatosis. Cancer J 15 (2009) 184-189
91. Sobin L.H., and Wittikind C. TMN classification of malignant tumours. 7th edn. (2010), Wiley and sons, London
92. Gunderson L.L., Jessup J.M., Sargent D.J., Greene F.L., and Stewart A.K. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol 28 (2010) 264-271
93. Le Voyer T.E., Sigurdson E.R., Hanlon A.L., et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 21 (2003) 2912-2919
94. Chang G.J., Rodriguez-Bigas M.A., Skibber J.M., and Moyer V.A. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst 99 (2007) 433-441
95. Prandi M., Lionetto R., Bini A., et al. Prognostic evaluation of stage B colon cancer patients is improved by an adequate lymphadenectomy: results of a secondary analysis of a large scale adjuvant trial. Ann Surg 235 (2002) 458-463
96. Quirke P., Steele R., Monson J., et al., on behalf of the MRC CR07/NCIC-CTG CO16 trial investigators and the NCRI colorectal cancer study group. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet 373 (2009) 821-828
97. Peeters K.C., Marijnen C.A., Nagtegaal I.D., et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 246 (2007) 693-701
98. Bosset J.F., Collette L., Calais G., et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355 (2006) 1114-1123
99. Rullier E., Laurent C., Bretagnol F., Rullier A., Vendrely V., and Zerbib F. Sphincter-saving resection for all rectal carcinomas: the end of the 2-cm distal rule. Ann Surg 241 (2005) 465-469
100. Chamlou R., Parc Y., Simon T., et al. Long-term results of intersphincteric resection for low rectal cancer. Ann Surg 246 (2007) 916-921
101. Cornish J.A., Tilney H.S., Heriot A.G., Lavery I.C., Fazio V.W., and Tekkis P.P. A meta-analysis of quality of life for abdominoperineal excision of rectum versus anterior resection for rectal cancer. Ann Surg Oncol 14 (2007) 2056-2068
102. Bretagnol F., Rullier E., Laurent C., Zerbib F., Gontier R., and Saric J. Comparison of functional results and quality of life between intersphincteric resection and conventional coloanal anastomosis for low rectal cancer. Dis Colon Rectum 47 (2004) 832-838
103. van D.P., Slors J.F., Taat C.W., et al. Prospective evaluation of anorectal function after total mesorectal excision for rectal carcinoma with or without preoperative radiotherapy. Am J Gastroenterol 97 (2002) 2282-2289
104. Nascimbeni R., Burgart L.J., Nivatvongs S., and Larson D.R. Risk of lymph node metastasis in T1 carcinoma of the colon and rectum. Dis Colon Rectum 45 (2002) 200-206
105. Tytherleigh M.G., Warren B.F., and Mortensen N.J. Management of early rectal cancer. Br J Surg 95 (2008) 409-423
106. Bach S.P., Hill J., Monson J.R., et al. A predictive model for local recurrence after transanal endoscopic microsurgery for rectal cancer. Br J Surg 96 (2009) 280-290
107. Leung K.L., Kwok S., Lam S.C.W., et al. Laparoscopic resection of rectosigmoid carcinoma: prospective randomised trial. Lancet 363 (2004) 1187-1192
108. Guillou P.J., Quirke P., Thorpe H., et al., for the MRC CLASICC trial group. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. Lancet 365 (2005) 1718-1726
109. Lacy A.M., Delgado S., Castells A., et al. The long-term results of a randomized clinical trial of laparoscopy-assisted versus open surgery for colon cancer. Ann Surg 248 (2008) 1-7
110. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med 350 (2004) 2050-2059
111. Hewett P.J., Allardyce R.A., Bagshaw P.F., et al. Short-term outcomes of the Australasian randomized clinical study comparing laparoscopic and conventional open surgical treatments for colon cancer: the ALCCaS trial. Ann Surg 248 (2008) 728-738
112. Jayne D.G., Guillou P.J., Thorpe H., et al. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. J Clin Oncol 25 (2007) 3061-3068
113. Jayne D.G., Brown J.M., Thorpe H., Walker J., Quirke P., and Guillou P.J. Bladder and sexual function following resection for rectal cancer in a randomized clinical trial of laparoscopic versus open technique. Br J Surg 92 (2005) 1124-1132
114. Nordlinger B., Sorbye H., Glimelius B., et al., for the EORTC Gastro-Intestinal Tract Cancer Group, Cancer Research UK, Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO), Australasian Gastro-Intestinal Trials Group (AGITG), Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371 (2008) 1007-1016
115. Negri F., Musolino A., Cunningham D., Pastorino U., Ladas G., and Norman A.R. Retrospective study of resection of pulmonary metastases in patients with advanced colorectal cancer: the development of a preoperative chemotherapy strategy. Clin Colorectal Cancer 4 (2004) 101-106
116. Ruers T., van Coevorden F., Pierie J., et al. Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): interim results of a randomised phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC). J Clin Oncol 26 suppl (2008) 4012 (abstr).
117. Sauer R., Becker H., Hohenberger W., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351 (2004) 1731-1740
118. MERCURY Study Group. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ 333 (2006) 779
119. Burton S., Brown G., Daniels I., et al. MRI identified prognostic features of tumors in distal sigmoid, rectosigmoid, and upper rectum: treatment with radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys 65 (2006) 445-451
120. Rutten H., Sebag-Montefiore D., Glynne-Jones R., et al. Capecitabine, oxaliplatin, radiotherapy, and excision (CORE) in patients with MRI-defined locally advanced rectal ademocarcinoma: results of an international multicenter phase II study. Proc ASCO 24 (2006) 153s (abstr).
121. Sebag-Montefiore D., Stephens R.J., Steele R., et al., on behalf of all the trial collaborators. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 373 (2009) 811-820
122. Marijnen C., Nagtegaal I.D., Kapiteijn E., et al., Cooperative investigators of the Dutch Colorectal Cancer Group. Radiotherapy does not compensate for positive resection margins in rectal cancer patients: report of a multicenter randomized trial. Int J Radiat Oncol Biol Phys 55 (2003) 1311-1320
123. Guillem J.G., Diaz-Gonzalez J., Minsky B.D., et al. cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. J Clin Oncol 26 (2008) 368-373
124. Birgisson H., Pahlman L., and Glimelius B. Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol 23 (2005) 8697-8705
125. Sauer R., and Rodel C. Chemoradiotherapy for rectal cancer. N Engl J Med 352 (2005) 509-511
126. Peeters K.C.M.J., Marijnen C., Nagtegaal I.D., et al., Dutch Colorectal Cancer group. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 246 (2007) 693-701
127. Bujko K., Nowacki M.P., Nasierowska-Guttmejer A., Michalski W., Bebenek M., and Kryj M. Long term results of a randomized trial comparing preoperative short-course radiotherapy with preperative conventionally fractionated chemoradiation for rectal cancer. BrJ Surg 93 (2006) 1215-1223
128. Bosset J.F., Collette L., Bardet E., Beny A., and Ollier J.C. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355 (2006) 1114-1123
129. Gerard J.P., Conroy T., and Bonnetain F. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 28 (2006) 4620-4625
130. Guillem J.G., Chessin D.B., Cohen A.M., et al. Long term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg 241 (2005) 829-838
131. Bertolini F., Bengala C., Losi L., et al. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys 68 (2007) 1455-1461
132. Johnston P.G. Prognostic markers of local relapse in rectal cancer: are we any further forward?. J Clin Oncol 24 (2006) 4049-4050
133. Glynne-Jones R., Wallace M., Livingstone J.I., and Thomas J.M. Complete clinical response after preoeprative chemoradiation in rectal cancer: is a "wait and see" policy justified?. Dis Colon Rectum 51 (2008) 10-20
134. Habr-Gama A., Santinho B., de Souza P.M., et al. Low rectal cancer. Impact of radiation and chemotherapy on surgical treatment. Dis Colon Rectum 41 (1998) 1087-1096
135. Ceelen W., Boterberg T., Pattyn P., et al. Neoadjuvant chemoradiation versus hyperfractionated accelerated radiotherapy in locally advanced rectal cancer. Ann Surg Oncol 14 (2007) 424-431
136. Meyer J., Czito B., Yin F.F., and Willett C. Advanced radiation therapy technologies in the treatment of rectal and anal cancer: intensity-modulated photon therapy and proton therapy. Clin Colorectal Cancer 6 (2007) 348-356
137. Aristu J.J., Arbea L., Rodriguez J., et al. Phase I-II trial of concurrent capeciabine and oxaliplatin with preoperative intensity modulated radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 71 (2008) 748-755
138. Callister M.D., Ezzell G.A., and Gunderson L.L. IMRT reduces the dose to small bowel and other pelvic organs in the preoperative treatment of rectal cancer. Int J Radiat Oncol Biol Phys 66 (2006) s290 (abstr).
139. NCCN Clinical Practice Guidelines in Oncology (2009). http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (accessed Nov 11, 2009).
140. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 345 (1995) 939-944
141. Twelves C., Wong A., Nowacki M.P., et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352 (2005) 2696-2704
142. Sargent D.J., Wieand H.S., Haller D.G., et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23 (2005) 8664-8670
143. Sargent D.J., Patiyil S., Yothers G., et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol 25 (2007) 4569-4574
144. Andre T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 (2004) 2343-2351
145. Andre T., Boni C., Navarro M., et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27 (2009) 3109-3116
146. Kuebler J.P., Wieand H.S., O'Connell M.J., et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25 (2007) 2198-2204
147. Haller D., Tabernero J., Maroun J., et al. First efficacy findings from a randomised phase III trial of capecitabine + oxaliplatin versus bolus 5FU/LV for stage III colon cancer (NO16968/XELOXA study). Eur J Cancer 7 suppl 3 (2009) 5LBA (abstr).
148. Land S.R., Kopec J.A., Cecchini R.S., et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 25 (2007) 2205-2211
149. McCleary N.J., Meyerhardt J., Green E., et al. Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II/III colon cancer: Findings from the ACCENT Database. Proc ASCO Meeting Abstracts 27 15 suppl (2009) 4010
150. Saltz L.B., Niedzwiecki D., Hollis D., et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 25 (2007) 3456-3461
151. Ychou M., Raoul J.L., Douillard J.Y., et al. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol 20 (2009) 674-680
152. Van C.E., Labianca R., Bodoky G., et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 27 (2009) 3117-3125
153. Cunningham D., and Starling N. Adjuvant chemotherapy of colorectal cancer. Lancet 370 (2007) 1980-1981
154. Quasar Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370 (2007) 2020-2029
155. Fields A.L., Keller A., Schwartzberg L., et al. Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer. J Clin Oncol 27 (2009) 1941-1947
156. Wolmark N., Yothers G., O'Connell M.J., et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. Proc ASCO Meeting Abstracts 27 18 suppl (2009) LBA4
157. Addition of Cetuximab to Standard Chemotherapy in Early-Stage Colon Cancer Shows No Benefit in Phase 3 Clinical Trial (2009). http://www.cancer.gov/newscenter/pressreleases/CetuximabClosure (accessed March 3, 2010).
158. Renehan A.G., Egger M., Saunders M.P., and O'Dwyer S.T. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ 324 (2002) 813
159. Jeffery G.M., Hickey B.E., and Hider P. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 1 (2002) CD002200.
160. Tsikitis V.L., Malireddy K., Green E.A., et al. Postoperative surveillance recommendations for early stage colon cancer based on results from the clinical outcomes of surgical therapy trial. J Clin Oncol 27 (2009) 3671-3676
161. Chau I., Allen M.J., Cunningham D., et al. The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. J Clin Oncol 22 (2004) 1420-1429
162. Van C.E., and Oliveira J. Primary colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. Ann Oncol 20 suppl 4 (2009) 49-50
163. Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22 (2004) 229-237
164. Cassidy J., Clarke S., az-Rubio E., et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26 (2008) 2006-2012
165. Porschen R., Arkenau H.T., Kubicka S., et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 25 (2007) 4217-4223
166. Grothey A., Sargent D., Goldberg R.M., and Schmoll H.J. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22 (2004) 1209-1214
167. Seymour M.T., Maughan T.S., Ledermann J.A., et al., for the FOCUS Trial Investigators and the National Cancer Research Institute Colorectal Clinical Studies Group. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 370 (2007) 143-152
168. Cunningham D., Sirohi B., Pluzanska A., et al. Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. Ann Oncol 20 (2009) 244-250
169. Folprecht G., Grothey A., Alberts S., Raab H.R., and Kohne C.H. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16 (2005) 1311-1319
170. Maughan T.S., James R.D., Kerr D.J., et al., on behalf of the Medical Research Council Colorectal Cancer Group. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet 361 (2003) 457-464
171. Tournigand C., Cervantes A., Figer A., et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 24 (2006) 394-400
172. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
173. Jonker D.J., O'Callaghan C.J., Karapetis C.S., et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 357 (2007) 2040-2048
174. Sobrero A.F., Maurel J., Fehrenbacher L., et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26 (2008) 2311-2319
175. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25 (2007) 1658-1664
176. Van Cutsem E., Kohne C.H., Hitre E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360 (2009) 1408-1417
177. Bokemeyer C., Bondarenko I., Makhson A., et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27 (2009) 663-671
178. Folprecht G., Gruenberger T., Bechstein W.O., et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11 (2010) 38-47
179. Maughan T., Adams R.A., Smith C.G., et al. Addition of cetuximab to oxaliplatin-based combination chemotherapy in patients with KRAS wild-type advanced colorectal cancer: a randomised superiority trial (MRC COIN). Eur J Cancer 7 suppl (2009) 6LBA (abstr).
180. Siena S., Cassidy J., Tabernero J., et al. Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared to FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial. Gastrointestinal Symposium (2010) 283 (abstr).
181. Peeters M., Price T.J., Hotko Y.S., et al. Randomized phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): patient-reported outcomes (PRO). Gastrointestinal Symposium (2010) 282 (abstr).
182. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
183. Giantonio B.J., Catalano P.J., Meropol N.J., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25 (2007) 1539-1544
184. Saltz L.B., Clarke S., az-Rubio E., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26 (2008) 2013-2019
185. Saltz L.B., Lenz H.J., Kindler H.L., et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 25 (2007) 4557-4561
186. Hecht J.R., Mitchell E., Chidiac T., et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27 (2009) 672-680
187. Tol J., Koopman M., Cats A., et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360 (2009) 563-572
188. Wilke H., Glynne-Jones R., Thaler J., et al. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study. J Clin Oncol 26 (2008) 5335-5343
189. Van Cutsem E., Rougier P., Kohne C.H., Stroh C., Schlichting M., and Bokemeyer C. A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy as 1st-line treatment for patients with metastatic colorectal cancer: results according to KRAS and BRAF mutation status. Eur J Cancer 7 (2009) 6077 (abstr).
190. Karapetis C.S., Khambata-Ford S., Jonker D.J., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359 (2008) 1757-1765
191. US Food and Drug Administration. http://www.fda.gov/ohrms/dockets/ac/08/slides/2008-4409s1-04-ImClone.pdf (accessed March 3, 2010).
192. Amado R.G., Wolf M., Peeters M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26 (2008) 1626-1634
193. Van Cutsem E., Lang I., Folprecht G., et al. Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): the influence of KRAS and BRAF biomarkers on outcome: Updated data from the CRYSTAL trial. Gastrointestinal Symposium (2010) 281 (abstr).
194. Grothey A., Sugrue M.M., Purdie D.M., et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 26 (2008) 5326-5334
195. Scappaticci F.A., Fehrenbacher L., Cartwright T., et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91 (2005) 173-180
196. Cetuximab for the first-line treatment of metastatic colorectal cancer (2009). http://guidance.nice.org.uk/TA176/Guidance/pdf/English (accessed Aug 26, 2009).
197. Bardelli A., and Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28 (2010) 1254-1261
198. Di N.F., Martini M., Molinari F., et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26 (2008) 5705-5712
199. Kohne C., Stroiakovski D., Chang-chien C., et al. Predictive biomarkers to improve treatment of metastatic colorectal cancer (mCRC): Outcomes with cetuximab plus FOLFIRI in the CRYSTAL trial. Proc ASCO Meeting Abstracts 27 (2009) 4068
200. Tejpar S., Bosman F., Delorenzi M., et al. Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial). Proc ASCO Meeting Abstracts 27 (2009) 4001
201. Popat S., Hubner R., and Houlston R.S. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23 (2005) 609-618
202. Bertagnolli M.M., Niedzwiecki D., Compton C.C., et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 27 (2009) 1814-1821
203. Ribic C.M., Sargent D.J., Moore M.J., et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349 (2003) 247-257
204. Sargent D.J., Marsoni S., Thibodeau S.N., et al. Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials. Proc ASCO Meeting Abstracts 26 15 suppl (2008) 4008
205. Jen J., Kim H., Piantadosi S., et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 331 (1994) 213-221
206. Ogunbiyi O.A., Goodfellow P.J., Herfarth K., et al. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol 16 (1998) 427-433
207. Popat S., and Houlston R.S. A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer 41 (2005) 2060-2070
208. Watanabe T., Wu T.T., Catalano P.J., et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344 (2001) 1196-1206
209. Halling K.C., French A.J., McDonnell S.K., et al. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 91 (1999) 1295-1303
210. Popat S., Zhao D., Chen Z., et al. Relationship between chromosome 18q status and colorectal cancer prognosis: a prospective, blinded analysis of 280 patients. Anticancer Res 27 (2007) 627-633
211. Ogino S., Nosho K., Irahara N., et al. Prognostic significance and molecular associations of 18q loss of heterozygosity: A cohort study of microsatellite stable colorectal cancers. J Clin Oncol 20 (2009) 4591-4598
212. Barratt P.L., Seymour M.T., Stenning S.P., et al., the UKCCCR AXIS trial collaborators. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet 360 (2002) 1381-1391
213. Alazzouzi H., Alhopuro P., Salovaara R., et al. SMAD4 as a prognostic marker in colorectal cancer. Clin Cancer Res 11 (2005) 2606-2611
214. Alhopuro P., Alazzouzi H., Sammalkorpi H., et al. SMAD4 levels and response to 5-fluorouracil in colorectal cancer. Clin Cancer Res 11 (2005) 6311-6316
215. Gaasenbeek M., Howarth K., Rowan A.J., et al. Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex changes and multiple forms of chromosomal instability in colorectal cancers. Cancer Res 66 (2006) 3471-3479
216. Trautmann K., Terdiman J.P., French A.J., et al. Chromosomal instability in microsatellite-unstable and stable colon cancer. Clin Cancer Res 12 (2006) 6379-6385